Varner was only able to stay on the medication using Social Security disability support. She said if she didn’t have ...

Roche has reported findings from Stage I of the Phase III OUtMATCH study of the immunoglobulin E (IgE)-targeting antibody Xolair (omalizumab) in people with multiple food allergies. Sponsored by ...

Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab) for immunoglobulin E-mediated food allergy in certain ...

Xolair (omalizumab) generated revenues of more ... which is available in markets in the US and EU as a subcutaneous injection lasting a few minutes, instead of a lengthy infusion.

The approved dose is 300 mg by subcutaneous injection every four weeks. "The EU approval of Xolair in CSU is truly exciting for patients with this chronic and debilitating skin disease," said ...